Bristol-Myers to pay $2.5 billion for Inhibitex

Bristol-Myers Squibb has agreed to pay about $2.5 billion in cash to acquire Inhibitex, the New York Times reports. Inhibitex makes a treatment for hepatitis C. The move comes as large pharmaceutical makers such as Bristol-Myers are looking to boost their offerings with more profitable specialty products. more